Table 2 The counts of real cases and mutations/aberrations in different genes across the five MN sub-categories: real AML, real MDS, real MDS/MPN, real MPN, and real CH.
Number of Real Non-CML Cases | 501 | 1,746 | 745 | 1,380 | 195 |
|---|---|---|---|---|---|
Myeloid Neoplasm Sub-Category | Real AML** | Real MDS | Real MDS/MPN | Real MPN | Real CH |
Total Number of Mutations/Aberrations | 1,188 | 3,027 | 1,564 | 1,889 | 215 |
ASXL1 | 31 (31 Cases) | 202 (196 Cases) | 107 (105 Cases) | 71 (66 Cases) | 14 (14 Cases) |
BCOR | 28 (27 Cases) | 58 (54 Cases) | 10 (10 Cases) | 6 (6 Cases) | 2 (2 Cases) |
CALR | 1 (1 Cases) | 17 (17 Cases) | 33 (33 Cases) | 145 (145 Cases) | — |
CBFB::MYH11* | 11 (11 Cases) | — | — | — | — |
CBL | 11 (10 Cases) | 21 (21 Cases) | 41 (40 Cases) | 9 (8 Cases) | 4 (4 Cases) |
CEBPA* | 28 (19 Cases) | 3 (3 Cases) | 1 (1 Cases) | 1 (1 Cases) | — |
CSF3R | 5 (5 Cases) | 4 (4 Cases) | 7 (7 Cases) | 10 (10 Cases) | — |
DEK::NUP214* | 3 (3 Cases) | — | — | — | — |
DNMT3A “R882” | 55 (54 Cases) | 103 (102 Cases) | 33 (33 Cases) | 34 (34 Cases) | 23 (23 Cases) |
DNMT3A-Others | 25 (24 Cases) | 97 (96 Cases) | 21 (20 Cases) | 22 (22 Cases) | 27 (27 Cases) |
ETV6 | 4 (4 Cases) | 9 (9 Cases) | 2 (2 Cases) | 3 (3 Cases) | 1 (1 Cases) |
EZH2 | 3 (2 Cases) | 21 (21 Cases) | 6 (6 Cases) | 8 (8 Cases) | 2 (2 Cases) |
FLT3 | 98 (94 Cases) | 2 (2 Cases) | 7 (7 Cases) | 12 (12 Cases) | — |
GATA2 | 3 (3 Cases) | 3 (3 Cases) | 1 (1 Cases) | 1 (1 Cases) | — |
IDH1 | 54 (54 Cases) | 48 (48 Cases) | 10 (10 Cases) | 2 (2 Cases) | 1 (1 Cases) |
IDH2 | 78 (78 Cases) | 91 (91 Cases) | 30 (30 Cases) | 30 (30 Cases) | 3 (3 Cases) |
IKZF1 | 2 (2 Cases) | — | — | — | — |
JAK2 Exon 12 | — | — | — | 7 (7 Cases) | — |
JAK2 “V617F” | 29 (29 Cases) | 96 (96 Cases) | 171 (171 Cases) | 957 (957 Cases) | — |
JAK3 | — | 2 (2 Cases) | 2 (2 Cases) | 1 (1 Cases) | — |
KIT | 6 (6 Cases) | 2 (2 Cases) | 8 (8 Cases) | 2 (2 Cases) | — |
KRAS | 25 (25 Cases) | 16 (16 Cases) | 46 (43 Cases) | 15 (15 Cases) | 7 (7 Cases) |
MLLT3::KMT2A* | 4 (4 Cases) | — | — | — | — |
MPL | 1 (1 Cases) | 21 (21 Cases) | 24 (24 Cases) | 44 (42 Cases) | — |
NF1 | 10 (10 Cases) | 8 (7 Cases) | 11 (10 Cases) | 4 (4 Cases) | 2 (2 Cases) |
NPM1* | 78 (78 Cases) | 6 (6 Cases) | 8 (8 Cases) | 8 (8 Cases) | — |
NRAS | 72 (66 Cases) | 18 (17 Cases) | 73 (68 Cases) | 33 (30 Cases) | 5 (5 Cases) |
PHF6 | 10 (10 Cases) | 19 (19 Cases) | 14 (14 Cases) | 2 (2 Cases) | 2 (2 Cases) |
PML::RARA* | 26 (26 Cases) | — | — | — | — |
PTPN11 | 28 (25 Cases) | 11 (10 Cases) | 9 (9 Cases) | 5 (4 Cases) | — |
RUNX1 | 65 (59 Cases) | 117 (101 Cases) | 47 (45 Cases) | 22 (19 Cases) | 1 (1 Cases) |
RUNX1::RUNX1T1* | 4 (4 Cases) | — | — | — | — |
SETBP1 | 9 (9 Cases) | 24 (24 Cases) | 32 (32 Cases) | 30 (30 Cases) | 2 (2 Cases) |
SF3B1 | 16 (16 Cases) | 433 (423 Cases) | 123 (120 Cases) | 69 (68 Cases) | 10 (10 Cases) |
SRSF2 | 69 (69 Cases) | 304 (304 Cases) | 182 (181 Cases) | 91 (91 Cases) | 8 (8 Cases) |
STAG2 | 23 (22 Cases) | 91 (85 Cases) | 20 (14 Cases) | 12 (12 Cases) | 2 (2 Cases) |
TET2 | 102 (77 Cases) | 635 (485 Cases) | 381 (279 Cases) | 150 (128 Cases) | 76 (64 Cases) |
TP53-Multi-Hit | 88 (70 Cases) | 131 (94 Cases) | 10 (7 Cases) | 26 (17 Cases) | — |
TP53-Single-VAF-Less-Than-50% | 31 (31 Cases) | 127 (127 Cases) | 9 (9 Cases) | 26 (26 Cases) | 15 (15 Cases) |
U2AF1 | 33 (32 Cases) | 218 (211 Cases) | 55 (54 Cases) | 22 (22 Cases) | 7 (7 Cases) |
WT1 | 16 (16 Cases) | 3 (3 Cases) | 2 (2 Cases) | 1 (1 Cases) | — |
ZRSR2 | 3 (3 Cases) | 66 (62 Cases) | 28 (28 Cases) | 8 (8 Cases) | 1 (1 Cases) |
